Form 4: Theravance Biopharma Exec Sells Shares for Tax Obligations

Aine Miller, SVP at Theravance Biopharma, disposed of 16,851 ordinary shares to cover tax liabilities from vested restricted stock units.

Summary

• Aine Miller, Senior Vice President, Development & Head of Ireland Office at Theravance Biopharma, Inc. (TBPH), reported a transaction involving ordinary shares.
• On February 20, 2026, Miller disposed of 16,851 ordinary shares at a price of $19.66 per share.
• This transaction was classified as a 'F' transaction code, indicating shares were withheld by the issuer to satisfy tax obligations arising from the vesting of previously granted restricted stock units.
• The transaction was not an open market sale.
• Following this transaction, Miller beneficially owns 184,161 ordinary shares directly.
• The transaction was made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral. The transaction is a routine tax-related withholding of shares upon RSU vesting and does not reflect a discretionary sale or provide new insights into the company's operational or financial health.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

StockSavvy.ai notes that the disposition of shares to cover tax obligations upon the vesting of restricted stock units is a common and routine event for executives. Such transactions are typically not indicative of management's sentiment regarding the company's future prospects or operational performance, but rather a standard mechanism for managing equity compensation.

Stakeholder Impact

• Shareholders: Minimal impact, as this is a routine, non-discretionary transaction for tax purposes and does not signal a change in the executive's confidence or the company's fundamentals.

Key Dates

Recommendation

The filing details a routine, non-discretionary sale of shares by an executive to cover tax obligations related to vested restricted stock units. This type of transaction does not provide new fundamental information about Theravance Biopharma, Inc. that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate as the core investment thesis remains unchanged based on this filing.

Keywords

Theravance Biopharma, TBPH, Form 4, Insider Transaction, Stock Sale, Tax Withholding, Restricted Stock Units, Aine Miller